Bambusa Therapeutics, Inc. closes Series A-2 financing of an undisclosed amount with backers including Athos KG and RA Capital Management to advance its bispecific antibodies for immunology.
Round Type
Series A
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Bambusa Therapeutics, Inc., a Boston-based biotech firm, has closed its Series A-2 financing round. The funding amount remains undisclosed. The company plans to use these funds to further develop bispecific antibodies aimed at treating chronic diseases. Key backers include a mixture of investment firms and platforms.
Quick answer
Bambusa Therapeutics raised an undisclosed amount in a Series A round, dated November 17, 2025. Investors: Salvia GmbH, Dawn Biopharma, Adar1 Capital Management, Invus, Janus Henderson Investors, BVF Partners L.P., Redmile Group and INCE Capital. Bambusa Therapeutics is based in Boston, Massachusetts, United States.
- How much did Bambusa Therapeutics raise?
- Bambusa Therapeutics raised an undisclosed amount in a Series A round on November 17, 2025.
- Who invested in Bambusa Therapeutics?
- Salvia GmbH, Dawn Biopharma, Adar1 Capital Management, Invus, Janus Henderson Investors, BVF Partners L.P., Redmile Group and INCE Capital are named as investors in this round.
- What does Bambusa Therapeutics do?
- Bambusa Therapeutics believes the I&I field is long overdue for innovative approaches and transformative therapeutics.
- Where is Bambusa Therapeutics based and how big is it?
- Bambusa Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 12 employees.
- Who are the decision-makers at Bambusa Therapeutics?
- Fundz holds 2 contacts at Bambusa Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Bambusa Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Dermata Therapeutics raised $4.1M on December 29, 2025.
- CASI Pharmaceuticals raised $5M on December 27, 2025.
- MAIA Biotechnology raised $1.5M on December 22, 2025.
- Rezubio Pharmaceuticals raised $20M (Series A) on December 19, 2025.
- Kodiak Sciences raised $160M (Post-IPO Equity) on December 18, 2025.
- LeonaBio, Inc. raised $90M (Funding Round) on December 18, 2025.
Who to call at Bambusa Therapeutics, and when
A new round usually means Bambusa Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Bambusa Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bambusa Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bambusa Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bambusa Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansBambusa Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.